US$ 22.94
glp-1 management platform startups 5 Startups Looking to Compete in the Obesity Space glp-1 management platforms startups Market
Description
In the semaglutide group, 569 out of 8803 patients (6.5%) experienced a primary cardiovascular end-point event, compared to 701 out of 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80

A healthy 30-year-old and a 70-year-old with heart disease are not the same prescription, and the framework pushes against treating them like they are

doi: 10.3748/wjg.14.563 52 BliddalSNielsenCHFeldt-RasmussenU

[DOI] [PMC free article] [PubMed] [Google Scholar] 97.Barrera JG, et al

Let me know other questions you have

Bydureon product information
